A New Age for MAGL  by Guzmán, Manuel
The recent developments described
above havemadeOBOC library screening
a much more efficient process. Indeed, it
is now realistic for a single person to
synthesize and screen a 100 million-
member library and obtain themost active
compound in a matter of weeks, without
the need of any elaborate robotic
systems. Although the methodologies
have been demonstrated with peptide
and peptoid libraries, they should be
readily applicable to any compound class,
as long as the compound structure can be
decoded by using the sample from
a single bead. For peptides and peptoids,
compound decoding has become trivial
due to the advent of several powerful
mass spectrometry-based techniques
(Paulick et al., 2006, Thakkar et al.,
2009). For small molecule libraries of 104
or lower diversity, several innovative en-
coding techniques have been developed
(Ohlmeyer et al., 1993, Song et al., 2003).
For larger small-molecule libraries (R105
diversity), hit identification remains a
significant challenge.
REFERENCES
Astle, J.M., Simpson, L.S., Huang, Y., Reddy,
M.M.,Wilson, R., Connell, S., Wilson, J., and Koda-
dek, T. (2010). Chem. Biol. 17, this issue, 38–45.
Chen, X., Tan, P.H., Zhang, Y., and Pei, D. (2009).
J. Comb. Chem. 11, 604–611.
Hintersteiner, M., Kimmerlin, T., Kalthoff, F.,
Stoeckli, M., Garavel, G., Seifert, J.-M., Meisner,
N.-C., Uhl, V., Buehler, C., Weidemann, T., and
Auer, M. (2009). Chem. Biol. 16, 724–735.
Lam, K.S., Salmon, S.E., Hersh, E.M., Hruby, V.J.,
Kazmierski, W.M., and Knapp, R.J. (1991). Nature
354, 82–84.
Ohlmeyer, M.H.J., Swanson, R.N., Dillard, L.W.,
Reader, J.C., Asouline, G., Kobayashi, R., Wigler,
M., and Still, W.C. (1993). Proc. Natl. Acad. Sci.
USA 90, 10922–10926.
Paulick, M.G., Hart, K.M., Brinner, K.M., Tjandra,
M., Charych, D.H., and Zuckermann, R.N. (2006).
J. Comb. Chem. 8, 417–426.
Song, A., Zhang, J.H., Labrilla, C.B., and Lam, K.S.
(2003). J. Am. Chem. Soc. 125, 6180–6188.
Thakkar, A., Cohen, A.S., Connolly, M.D., Zucker-
mann, R.N., and Pei, D. (2009). J. Comb. Chem.
11, 294–302.
Wang, X., Peng, L., Liu, R., Xu, B., and Lam, K.S.
(2005). J. Pept. Res. 65, 130–138.
A New Age for MAGL
Manuel Guzma´n1,*
1Department of Biochemistry and Molecular Biology I and Centro de Investigacio´n Biome´dica en Red sobre Enfermedades
Neurodegenerativas (CIBERNED), School of Biology, Complutense University, 28040 Madrid, Spain
*Correspondence: mgp@bbm1.ucm.es
DOI 10.1016/j.chembiol.2010.01.001
Monoacylglycerol lipase (MAGL) has been known for its participation in triacylglycerol breakdown and endo-
cannabinoid deactivation. Now Nomura et al. show that cancer cells can hijack MAGL to produce oncogenic
lipid messengers. This exciting finding raises important pathophysiological questions.
Lipids are traditionally envisaged as
energy fuels, membrane building blocks,
and members of the steroid hormone
family. However, most researchers rarely
appreciate the high structural diversity
and precise functional specialization of
lipid metabolites. After the molecular
characterization of a first generation of
local (e.g., prostanoids) and intracellular
(e.g., diacylglycerols [DAGs]) lipid mes-
sengers, a second group of lipids in-
volved in crucial aspects of cell-to-cell
communication has emerged during the
past two decades. Examples include
glycerol- and sphingoid base-backboned
Figure 1. OBOC Library Screening by Magnetic Bead Sorting Coupled with Microarray
Analysis
Library beads incubated with the target protein are rendered as a suspension in a tube. Amagnet is placed
next to the tube and the beads are allowed to settle. Negative beads settle to the bottom while the hits
remain on the wall of the tube.
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lysophospholipids such as lysophos-
phatidic acid (LPA) and sphingosine-
1-phosphate (S1P), respectively, and
new arachidonic acid bioactive deriva-
tives such as endocannabinoids
(Figure 1) (Piomelli et al., 2007; Takabe
et al., 2008). These compounds are
produced inside the cells, and their
levels are tightly tuned by a complex
balance between their synthesis and
their degradation through a plethora of
acyltransferases, lipases, lipid kinases,
lipidphosphatases, andother enzymes.
Once generated, these lipids can be
releasedandact extracellularly in anau-
tocrine/paracrine manner by engaging
and activating G protein-coupled
receptors (GPCRs), the largest super-
family of cell surface molecules in-
volved in signal transduction (Dorsam
and Gutkind, 2007; http://www.iuphar.
org). Accruing evidence supports that
this ‘‘inside-out’’ signaling by local lipid
mediators may play a role in many
human diseases, including cancer. For
example, prostaglandin E2 (PGE2),
S1P, and LPA induce cell proliferation,
survival, and migration/invasion, thus
favoring tumor growth, angiogenesis,
and metastasis in animal models of
cancer (Figure 1, in black) (Dorsam
and Gutkind, 2007). In contrast, canna-
binoid-receptor engagement usually
evokes the opposite effects, at least
under most cellular contexts (Figure 1,
in red) (Guzma´n, 2003).
Monoacylglycerol lipase (MAGL) has
long been known for its participation
in the breakdown of adipose triacylgly-
cerol (TAG) stores, a key feature of meta-
bolic homeostasis that, by providing
tissues with free fatty acid (FFA) fuel,
allows adaption to glucose deprivation
periods (Figure 2A) (Tornqvist and Bel-
frage, 1976). However, the regulatory
role of MAGL in this process seems to
be negligible, as hydrolysis of the TAG
sn-1 and sn-3 ester bonds by hormone-
sensitive lipase (HSL) constitutes the
pace-setting and hormonally-controlled
step of lipolysis. After standing as a
‘‘dull’’ enzyme for many years, MAGL
was ‘‘rediscovered’’ by Piomelli and
coworkers, who showed that it plays
a pivotal role in the deactivation of the en-
docannabinoid 2-arachidonoylglycerol
(2-AG), a neuronal messenger that tunes
the functionality and plasticity of many
synapses (Figure 2B) (Dinh et al., 2002).
Now, Nomura et al. (2010) provide a new
fascinating function for MAGL: the control
of FA release from lipid stores in cancer
cells, which allows them to produce the
aforementioned lipid signals that promote
tumor growth (Figure 2C).
Human tumors are highly heteroge-
neous in terms of nutrient supply and
oxygenation, and develop progressive
alterations in energetic and proliferative
statuses as well as in the vascular
network. Among dysregulated metabolic
routes that correlate with malignancy,
the shift from glucose oxidative metabo-
lism to lactic acid-directed glycolysis
(the Warburg effect) is so far the best
documented example. The development
of a lipogenic phenotype, characterized
by enhanced FA synthesis de novo, also
favors tumor growth in animal models
and correlates with a poor prognosis in
various types of human cancers (Menen-
dez and Lupu, 2007). Enhanced lipo-
genesis may conceivably contribute
to tumor growth by multiple mecha-
nisms, including the generation of
energy substrates, membrane building
blocks, and oncogenic lipid precursors.
As newly synthesized FAs are readily
incorporated into cellular lipid stores,
Nomura et al. (2010) reasoned that
cancer cells should possess a comple-
mentary lipolytic pathway to liberate
fatty acyl moieties from those reser-
voirs for signaling purposes. By using
an elegant proteomic approach based
on serine hydrolase activity-directed
probes, they found that, among the
dozens of serine hydrolases detected
in their analyses, MAGL was consis-
tently elevated in aggressive versus
nonaggressive cancer cell lines, and
accounted for the striking depletion of
MAGs and enrichment of FFAs found
in aggressive cells. Genetic or pharma-
cological blockade of MAGL in aggres-
sive cells rendered them FFA-depleted
and less malignant, while ectopic
expression of MAGL in nonaggressive
cells turned them FFA-enriched and
more malignant. Of note, substantial
experimental evidence was provided
to favor the notion that MAGL
supports the malignant properties of
cancer cells by maintaining tonically
elevated levels of FFAs, which, in
turn, become mostly channeled to
the production of various oncogenic
lipid messengers, such as PGE2 and
LPA, rather than to fuel b-oxidation,
sustain glycolysis, or generate mem-
brane lipids, at least in the cancer cells
tested (Figure 2C).
These hallmark observations by
Nomura et al. (2010) raise fascinating
conceptual and translational questions
at the interface of the lipid metabolism
and oncology fields. Let us mention three.
First, the authors found thatMAGL activity
and FFA levels are elevated in high-grade
versus benign human ovarian tumors.
How do this newly discovered MAGL-
FFA pathway and its associated sec-
ondary lipidomic signatures work in dif-
ferent types of cancer cells and their
neighboring niches at different tumor
initiation/progression stages? Plausible
candidates to explore include colorectal
and prostate tumors, in which MAGL
could tune the levels of the protumori-
genic lipids PGE2 and LPA (Dorsam and
Figure 1. An Array of Local Lipid Messengers
Controls Tumor Progression via GPCRs
Various lipid messengers are exported from cells and
act in a local manner by engaging specific GPCRs.
These signaling events usually evoke protumor
responses such as cell proliferation, survival, and
migration/invasion (in black). Cannabinoid-receptor
engagement can exert antitumor effects (in red).
eCB, endocannabinoid; LPC, lysophosphatidylcho-
line; LPI, lysophosphatidylinositol. Other abbreviations
are in the text.
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Gutkind, 2007), and perhaps
of antitumorigenic endocan-
nabinoids (Guzma´n, 2003;
Wang et al., 2008). Second,
their study also unveiled that
the low FFA levels and
impaired growth of MAGL
knocked-down cancer cells
in xenografted mice can be
rescued by feeding the
animals a high-fat diet. What
is the precise role of the
MAGL-FFA connection in the
crosstalk between obesity
and tumorigenesis? Its
possible link with dietary
restriction and the oncogenic
phosphatidylinositol 3-kinase
pathway (Kalaany and Saba-
tini, 2009) could specifically
be examined. Third, it was
also shown that MAGL-
silenced cancer cells display
enhanced sensitivity to the antimigratory
and antisurvival effects of an epidermal
growth factor receptor tyrphostin. Could
MAGL inhibitors render human tumors
more responsive to the antineoplastic
action of tyrosine kinase-targeted chemo-
therapeutic drugs? Although acute/
pharmacological and sustained/genetic
loss of MAGL function generated some-
what distinct metabolomic profiles in the
cancer cells studied, the work by Nomura
et al. (2010) turns MAGL into an unex-
pected and exciting new candidate for
cancer therapy.
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Brownell et al. (2010) elucidate the mechanism of action of MLN4924, a NEDD8-activating enzyme inhibitor.
MLN4924 requires the activity of the enzyme to generate a NEDD8-adenylate analog that potently and selec-
tively shuts down this posttranslational modification system.
The covalent modification of proteins with
ubiquitin (Ub) and ubiquitin-like proteins
(UbLs) is widely appreciated as a major
eukaryotic posttranslational regulatory
mechanism. To date, nine classes of
UbLs with varying degrees of identity to
Ub have been identified in humans (Schul-
man and Harper, 2009). In addition to
Ub’s well appreciated role in promoting
protein destruction by the 26S protea-
some, Ub and UbLs have numerous other
functions to rapidly and conditionally alter
protein function, such as changing protein
localization, regulating other posttransla-
tional modifications, and modulating
protein-protein interactions.
Ub and UbLs share similar enzymatic
mechanisms for their conjugation onto
target proteins. Their entry into a conjuga-
tion pathway first requires ATP-dependent
activation through the formation of an ad-
enylate intermediate in the nucleotide
binding pocket of their cognate E1 (acti-
vating enzyme) (Ciechanover et al., 1981;
Haas et al., 1982). After this occurs, the
activated molecule is transferred onto the
catalytic cysteine of E1, an acceptor
Figure 2. The Three Ages of MAGL
(A) MAGL catalyzes the final step of lipolysis in adipocytes, thus providing
tissues with FFA fuel.
(B) MAGL deactivates 2-AG in neurons, thus tuning endocannabinoid
signaling.
(C) MAGL controls FFA generation in cancer cells, thus allowing them to
produce oncogenic lipid signals.
AA, arachidonic acid; AT, acyltransferase; COX, cylooxygenase; DAGL, sn-1
DAG lipase; Pase, lipid phosphatase. Other abbreviations are in the text.
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